

**HEIDELBERG HEALTH ECONOMICS SUMMER SCHOOL
2026**

Bruneck, South Tyrol / Alto Adige, Italy
Enhanced Program for June 25-27, 2026

NOBIS Conference Center at NOI Techpark
Europastrasse 9 / Via Europa 9, I-39031 Bruneck / Brunico

**Applied Health Economics
& Health Technology Assessment**

A Systematic Introduction

Concepts, Issues & Challenges, Potential Solutions



University of Heidelberg

Faculty (June 2026 Program)

- Prof. **Michael Schlander**¹ (Heidelberg & Wiesbaden, Germany)
- Prof. **Maarten Postma** (Groningen, The Netherlands)
- Dr. **Ramon Schäfer** (Heidelberg & Wiesbaden, Germany)
- **Min Wai Lwin** (Heidelberg, Germany)
- **Anett Molnar** (Heidelberg, Germany)

¹Scientific Program Chair

Program

Thursday, June 25, 2026

Registration of Participants
at NOBIS Conference Center, Bruneck / Brunico

International Health Care Systems

Financing Health Care – International Systems, Trends and Challenges

Group Work / Exercise I

The Ethics of Priority-Setting (Case Study and Analysis)

The Economic Evaluation of Health Care Programs

The Need to Set Limits and Economic Analyses

Summer School Evening Reception

«20 Years Heidelberg Health Economics Schools»

at Bruneck Castle – including a guided tour
at the RIPA Messner Mountain Museum

Friday, June 26, 2026

Cost Effectiveness Analysis (CEA)

Health-Adjusted Life Years (HALYs), Incremental Cost Effectiveness Ratios (ICERs), Decision Analysis and Uncertainty, Value of Information Analyses

Group Work / Exercises II-III

Health-Related Quality of Life (HRQoL) and Patient-Reported Outcomes (PROs), Measurement Instruments, Multi-Attribute Utility (MAU) for Health Economic Evaluation; Group Work Conducting a Cost Effectiveness Analysis

Costing in Theory and Practice

Group Work / Exercise IV

Analyzing a Published Costing Study

Saturday, June 27, 2026

Group Work / Exercise V / Case Studies

Health Technology Assessments in Practice I-III

U.S. MFN Policy, England and Wales: NICE, European Union: Joint Clinical Assessments (JCAs), Germany: IQWiG/GBA, France: HAS

Major Challenges & Potential Solutions

Rare Diseases & Orphan Medicinal Products (OMPs), Reserve Antibiotics, Wide-Spread Disorders (Diabetes, Hypertension, Dementia), Precision Medicine & Advanced Therapy Medicinal Products (ATMPs), Cancer

The Ethics of Priority-Setting Revisited

Health Opportunity Cost, Cost Effectiveness Thresholds, the «Value of a Statistical Life Year», Sources of Social Value beyond QALY Gains

Navigating Market Access in the New Environment

Venue 2026

